Business Description
Precigen Inc
NAICS : 541714
SIC : 8731
Compare
Compare
Traded in other countries / regions
I5X.Germany
•
PGEN.USA
Description
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.56 | |||||
| Equity-to-Asset | 0.17 | |||||
| Debt-to-Equity | 3.73 | |||||
| Debt-to-EBITDA | -2.84 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -7.6 | |||||
| Beneish M-Score | -3.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.4 | |||||
| 3-Year EBITDA Growth Rate | 50.8 | |||||
| 3-Year EPS without NRI Growth Rate | 44.7 | |||||
| 3-Year FCF Growth Rate | 37.1 | |||||
| 3-Year Book Growth Rate | -38.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.3 | |||||
| 9-Day RSI | 32.33 | |||||
| 14-Day RSI | 39.38 | |||||
| 6-1 Month Momentum % | 12.62 | |||||
| 12-1 Month Momentum % | -52.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.51 | |||||
| Quick Ratio | 5.5 | |||||
| Cash Ratio | 3.86 | |||||
| Days Inventory | 70.45 | |||||
| Days Sales Outstanding | 83.78 | |||||
| Days Payable | 31.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 38.94 | |||||
| Operating Margin % | -107.66 | |||||
| Net Margin % | -113.59 | |||||
| ROE % | -86.94 | |||||
| ROA % | -25.52 | |||||
| ROIC % | -37.73 | |||||
| ROC (Joel Greenblatt) % | -163.85 | |||||
| ROCE % | -26.26 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.41 | |||||
| PB Ratio | 8.17 | |||||
| EV-to-EBIT | -6.32 | |||||
| EV-to-EBITDA | -7.46 | |||||
| EV-to-Revenue | 6.79 | |||||
| EV-to-Forward-Revenue | 42.64 | |||||
| EV-to-FCF | -7.89 | |||||
| Earnings Yield (Greenblatt) % | -15.82 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PGEN
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 80.714 | ||
| EPS (TTM) ($) | -0.47 | ||
| Beta | 2.08 | ||
| Volatility % | 71.63 | ||
| 14-Day RSI | 39.38 | ||
| 14-Day ATR ($) | 0.199582 | ||
| 20-Day SMA ($) | 2.4375 | ||
| 12-1 Month Momentum % | -52.47 | ||
| 52-Week Range ($) | 1.12 - 5.6 | ||
| Shares Outstanding (Mil) | 208.15 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Precigen Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Precigen Inc Analysis
Share your researchHeadlines
See More
No news.